<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>release-dividend.txt
<DESCRIPTION>PRESS RELEASE DATED OCTOBER 25, 2012
<TEXT>
     TECHNE CORPORATION DECLARES DIVIDEND AND ANNOUNCES AN INCREASE
                    IN ITS SHARE REPURCHASE PROGRAM


Minneapolis/October 25, 2012/ -- Techne Corporation (NASDAQ:TECH) announced
that its Board of Directors has decided to pay a dividend of $0.30 per share
for the quarter ended September 30, 2012.  The quarterly dividend will be
payable November 19, 2012 to all common shareholders of record on November 5,
2012.  Future cash dividends will be considered by the Board of Directors on
a quarterly basis.

Techne's Board of Directors also authorized the repurchase of an additional
$100 million of the Company's common stock in connection with its ongoing
share repurchase program, which does not have an expiration date. Including
the above amount, the total share repurchase authorization remaining is
approximately $127 million. Repurchases under the program will be at the
discretion of management and may be made in open market, pursuant to one or
more 10b5-1 plans, structured transactions, privately negotiated transactions
or otherwise, from time to time, depending on market conditions.  The stock
repurchase program may be modified or discontinued at any time.  The share
repurchase will be funded with a portion of the Company's existing cash and
available-for-sale investments.


              *  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has three operating
subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville,
California, Boston Biochem, Inc., located in Cambridge, Massachusetts and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. Boston Biochem is a leading developer of
ubiquitin-related research products. R&D China and R&D Europe distribute
biotechnology products.  R&D Europe has two subsidiaries, Tocris Holding, Ltd
(Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.
Tocris is a leading supplier of reagents for non-clinical life science
research.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854




</TEXT>
</DOCUMENT>
